Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Medicaid reimbursements, pharmacy benefit margins or risk-adjustment accruals across dozens of filings can overwhelm even seasoned analysts. Centene鈥檚 disclosures span hundreds of pages, and locating a single note on state contract renewals often feels like finding a needle in a haystack. That鈥檚 why investors searching for 鈥淐entene SEC filings explained simply鈥� or wondering 鈥渨here to read a Centene quarterly earnings report 10-Q filing鈥� start here.
Stock Titan鈥檚 AI-powered analysis converts complex language into clear takeaways. Uploads from EDGAR trigger real-time alerts, so 鈥淐entene Form 4 insider transactions real-time鈥� appear within minutes. Our platform highlights what matters in each document: the medical loss ratio buried in a 鈥淐entene annual report 10-K simplified鈥�, contract wins detailed in a 鈥淐entene 8-K material events explained鈥�, or share purchases flagged under 鈥淐entene insider trading Form 4 transactions鈥�. Need a quick view of executive equity moves? The dashboard aggregates 鈥淐entene executive stock transactions Form 4鈥� alongside context, saving hours of manual work.
Beyond form names, we connect filings to Centene鈥檚 business drivers. AI summaries break down Medicaid redetermination impacts quarter by quarter for 鈥淐entene earnings report filing analysis鈥�, spotlight shifts in premium revenue across states, and surface board proposals inside the 鈥淐entene proxy statement executive compensation鈥� section. Whether you鈥檙e a portfolio manager comparing MCO peers or a policy analyst 鈥渦nderstanding Centene SEC documents with AI鈥�, you鈥檒l find every 10-K, 10-Q, 8-K and Form 4鈥攚ith plain-English insights鈥攗pdated the moment Centene hits send.
Centene Corporation (CNC) 鈥� Form 4 insider filing
Director Kenneth A. Burdick reported a modest open-market acquisition of 556 Centene common shares on 30 June 2025 (transaction code A). The shares were acquired at a stated price of $0.00, suggesting the issuance relates to compensation or dividend reinvestment rather than a cash purchase. Following the transaction, Burdick鈥檚 direct ownership increases to 367,052.924 shares. He also reports 86,498 indirect shares held through Burdick Family LLC, bringing his aggregated economic interest to roughly 453.6 thousand shares.
The filing also discloses an existing stock option for 10,000 shares with a strike price of $80.57, exercisable from 7 Feb 2025 and expiring 7 Feb 2032. No new derivative transactions were recorded.
While insider purchases are generally viewed as a confidence signal, the 556-share addition represents less than 0.2 % of Burdick鈥檚 current stake and is immaterial to Centene鈥檚 overall float. The transaction therefore carries limited fundamental impact but modestly reinforces management鈥搒hareholder alignment.
Centene Corporation (CNC) 鈥� Form 4 insider activity
Director Christopher J. Coughlin reported one transaction dated 30 June 2025. He acquired 556 shares of Centene common stock at a stated price of $0, indicating the shares were received without cash consideration (e.g., settlement of equity awards as reflected by the filing). Following the transaction, Mr. Coughlin鈥檚 direct holdings increased to 11,435.926 shares. The filing also discloses indirect ownership of 30,054 shares held in a grantor-retained annuity trust (GRAT) for the benefit of Mr. Coughlin and his adult children, for which he is sole trustee.
Table II lists a previously granted option for 10,000 shares with a $80.57 exercise price, exercisable beginning 7 Feb 2025 and expiring 7 Feb 2032. No new derivative transaction was reported in this filing.
Key takeaways for investors
- The filing records a modest increase in insider ownership without any share sales.
- Cumulative direct and indirect equity exposure now totals ~41,490 shares, aligning director interests with shareholders.
- No material change to option positions; the 10,000-share option remains outstanding.
The transaction is routine in size relative to Centene鈥檚 market capitalization but may be interpreted as a marginally positive signal given the absence of dispositions.
Centene Corporation (CNC) 鈥� Form 4 insider activity
Director Christopher J. Coughlin reported one transaction dated 30 June 2025. He acquired 556 shares of Centene common stock at a stated price of $0, indicating the shares were received without cash consideration (e.g., settlement of equity awards as reflected by the filing). Following the transaction, Mr. Coughlin鈥檚 direct holdings increased to 11,435.926 shares. The filing also discloses indirect ownership of 30,054 shares held in a grantor-retained annuity trust (GRAT) for the benefit of Mr. Coughlin and his adult children, for which he is sole trustee.
Table II lists a previously granted option for 10,000 shares with a $80.57 exercise price, exercisable beginning 7 Feb 2025 and expiring 7 Feb 2032. No new derivative transaction was reported in this filing.
Key takeaways for investors
- The filing records a modest increase in insider ownership without any share sales.
- Cumulative direct and indirect equity exposure now totals ~41,490 shares, aligning director interests with shareholders.
- No material change to option positions; the 10,000-share option remains outstanding.
The transaction is routine in size relative to Centene鈥檚 market capitalization but may be interpreted as a marginally positive signal given the absence of dispositions.
Centene Corporation (CNC) 鈥� Form 4 insider activity
Director Christopher J. Coughlin reported one transaction dated 30 June 2025. He acquired 556 shares of Centene common stock at a stated price of $0, indicating the shares were received without cash consideration (e.g., settlement of equity awards as reflected by the filing). Following the transaction, Mr. Coughlin鈥檚 direct holdings increased to 11,435.926 shares. The filing also discloses indirect ownership of 30,054 shares held in a grantor-retained annuity trust (GRAT) for the benefit of Mr. Coughlin and his adult children, for which he is sole trustee.
Table II lists a previously granted option for 10,000 shares with a $80.57 exercise price, exercisable beginning 7 Feb 2025 and expiring 7 Feb 2032. No new derivative transaction was reported in this filing.
Key takeaways for investors
- The filing records a modest increase in insider ownership without any share sales.
- Cumulative direct and indirect equity exposure now totals ~41,490 shares, aligning director interests with shareholders.
- No material change to option positions; the 10,000-share option remains outstanding.
The transaction is routine in size relative to Centene鈥檚 market capitalization but may be interpreted as a marginally positive signal given the absence of dispositions.
Centene Corporation (CNC) Form 4 filing: Director Frederick H. Eppinger reported the acquisition of 463 shares of common stock on 06/30/2025 at a stated price of $0.00, indicating an equity award rather than an open-market purchase. Following the transaction, Eppinger directly owns 359,042.658 shares, which includes 5,965 restricted stock units (RSUs) subject to future vesting. No derivative securities transactions were reported. The filing was signed by attorney-in-fact Christopher A. Koster on 07/02/2025.
The transaction modestly increases the director鈥檚 stake by approximately 0.13%, providing incremental alignment with shareholder interests but does not represent a market-based purchase. No other insider transactions or material events were disclosed in this short-form filing.
Centene Corporation (CNC) Form 4 filing: Director Frederick H. Eppinger reported the acquisition of 463 shares of common stock on 06/30/2025 at a stated price of $0.00, indicating an equity award rather than an open-market purchase. Following the transaction, Eppinger directly owns 359,042.658 shares, which includes 5,965 restricted stock units (RSUs) subject to future vesting. No derivative securities transactions were reported. The filing was signed by attorney-in-fact Christopher A. Koster on 07/02/2025.
The transaction modestly increases the director鈥檚 stake by approximately 0.13%, providing incremental alignment with shareholder interests but does not represent a market-based purchase. No other insider transactions or material events were disclosed in this short-form filing.
BlackRock MuniVest Fund, Inc. (NYSE: MVF) has triggered its discount-management program and will launch an issuer tender offer for 2.5% of its outstanding common shares. The trigger was activated because the Fund鈥檚 shares traded at an average daily discount of -7.60% to net asset value (NAV) during the 1 April 鈥� 30 June 2025 measurement period, exceeding the 7.50% threshold. The tender offer will commence 15 July 2025 and expire 15 August 2025 at 5:00 p.m. ET, unless extended. Shareholders who tender will receive 98% of NAV calculated on the first business day following the expiration (or any extension) of the offer. If tenders exceed 2.5% of shares outstanding, purchases will be prorated. Payment is expected within five business days after expiration.
The initiative is intended to narrow MVF鈥檚 market discount, enhance long-term shareholder value and provide near-term liquidity, although the Fund explicitly notes that no assurance can be given regarding any discount reduction. Full terms will be detailed in the Offer to Purchase and related Schedule TO filings that will become available on the SEC鈥檚 website once the offer begins.
FAQ
What is the current stock price of Centene Del (CNC)?
What is the market cap of Centene Del (CNC)?
What is Centene Corporation's primary business focus?
How does Centene generate revenue?
What differentiates Centene from its competitors?
What challenges does Centene face?
What opportunities exist for Centene?
